Abpro Holdings (NASDAQ: ABP) CMO furloughed and employment ending November 2025

Rhea-AI Filing Summary

Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed and will be leaving the company. Effective September 30, 2025, the company placed him on furlough through November 30, 2025, during which he will not perform any duties or responsibilities associated with his role. The filing states that his employment will be terminated effective November 30, 2025, signaling a planned transition away from this key executive position.

Positive

• None.

Negative

• Chief Medical Officer departure: Abpro furloughed its Chief Medical Officer effective September 30, 2025, and states his employment will be terminated effective November 30, 2025, indicating turnover in a key executive role.

Insights

Corporate governance analyst

Abpro’s Chief Medical Officer is being furloughed and then terminated, signaling leadership turnover in a key role.

Abpro Holdings, Inc. reports that Chief Medical Officer Dr. Robert J. Markelewicz, Jr. was furloughed effective September 30, 2025, with his employment to end on November 30, 2025. During the furlough, he will not perform any duties or responsibilities associated with his role, which means the company will be without its named CMO functions over this period.

The departure of a chief medical officer can matter for companies whose strategy depends on clinical development and medical leadership, though this filing does not provide reasons or detail on succession. The impact on operations or strategy will depend on how responsibilities are reassigned and whether a replacement or interim leader is appointed, which may be clarified in subsequent company disclosures.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false 0001893219 0001893219 2025-09-30 2025-09-30 0001893219 ABP:SharesOfCommonStockParValue0.0001PerShareMember 2025-09-30 2025-09-30 0001893219 ABP:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 30, 2025

Abpro Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41224		87-1013956
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

100 Summit Drive Burlington, MA		01803
(Address of principal executive offices)		(Zip Code)

1-800-396-5890

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Shares of Common Stock, par value $0.0001 per share		ABP		The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50		ABPWW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 30, 2025, Abpro Holdings, Inc. (the “Company”) furloughed Robert J. Markelewicz, Jr., M.D., M.M.Sc., the Company’s Chief Medical Officer, effective September 30, 2025 until November 30, 2025. During the furlough period, Dr. Markelewicz will not perform any duties or responsibilities associated with his role. Dr. Markelewicz’s employment will be terminated effective November 30, 2025.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABPRO HOLDINGS, INC.
	By:	/s/ Miles Suk
	Name:	Miles Suk
	Title:	Chief Executive Officer
Dated: October 2, 2025

2

FAQ

What executive change did Abpro Holdings (ABP) disclose in this 8-K?

Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed effective September 30, 2025, and that his employment will be terminated effective November 30, 2025.

When did the furlough of Abpro’s Chief Medical Officer begin and end?

The furlough of Abpro’s Chief Medical Officer began on September 30, 2025 and is scheduled to continue until November 30, 2025, at which time his employment will be terminated.

Will Abpro’s Chief Medical Officer perform any duties during the furlough period?

No. The company states that during the furlough period, from September 30, 2025 to November 30, 2025, Dr. Markelewicz will not perform any duties or responsibilities associated with his role as Chief Medical Officer.

Who is the executive affected by this Abpro (ABP) leadership change?

The executive affected is Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., who serves as Chief Medical Officer of Abpro Holdings, Inc.

Did Abpro Holdings explain why the Chief Medical Officer is being furloughed and terminated?

The disclosure states the timing and terms of the furlough and termination for the Chief Medical Officer but does not provide reasons for this employment action in the excerpt provided.

Who signed the Abpro 8-K reporting the Chief Medical Officer’s departure?

The report was signed on behalf of Abpro Holdings, Inc. by Miles Suk, who is identified as the company’s Chief Executive Officer.